Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pfister

Showing results (361-370 of 380) with videos related to

Pageof 38
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2014
[CCAFU Recommendations 2013: Upper urinary tract carcinoma]C Pfister, M Roupret, Y Neuzillet, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemiaP Sonneveld, A Burnett, P Vossebeld, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|January 6, 2021
A multicentre cross-sectional descriptive study evaluating the cardiovascular risk profile of preoperatively identified patients with hypertensionS Govender, C Pfister, B Rayner, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]T Seisen, E Compérat, P Colin, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]P Gimel, M Gross-Goupil, L Geoffrois, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 25, 2010
[What's new in 2009 about urothelial tumors? Live from EAU, AUA and ASCO, ASCO-GU]D Amsellem-Ouazana, C Theodore, J Irani, et al.
ESMO Open|May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA studyT Decker, C Brucker, A Engel, et al.
The Journal of Allergy and Clinical Immunology|April 22, 2018
Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathologyMelissa H Bloodworth, Mark Rusznak, Connor C Pfister, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 27, 2008
[Do broader indications for partial nephrectomy result in excess morbidity?]G Verhoest, M Crepel, J-C Bernhard, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 1, 2011
[Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function outcome in tumors larger than 4 cm]F Boulière, M Crepel, P Bigot, et al.
Pageof 38

Showing results (361-370 of 380) with videos related to

Sort By:
Pageof 38
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2014
[CCAFU Recommendations 2013: Upper urinary tract carcinoma]C Pfister, M Roupret, Y Neuzillet, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemiaP Sonneveld, A Burnett, P Vossebeld, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|January 6, 2021
A multicentre cross-sectional descriptive study evaluating the cardiovascular risk profile of preoperatively identified patients with hypertensionS Govender, C Pfister, B Rayner, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]T Seisen, E Compérat, P Colin, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]P Gimel, M Gross-Goupil, L Geoffrois, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 25, 2010
[What's new in 2009 about urothelial tumors? Live from EAU, AUA and ASCO, ASCO-GU]D Amsellem-Ouazana, C Theodore, J Irani, et al.
ESMO Open|May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA studyT Decker, C Brucker, A Engel, et al.
The Journal of Allergy and Clinical Immunology|April 22, 2018
Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathologyMelissa H Bloodworth, Mark Rusznak, Connor C Pfister, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 27, 2008
[Do broader indications for partial nephrectomy result in excess morbidity?]G Verhoest, M Crepel, J-C Bernhard, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 1, 2011
[Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function outcome in tumors larger than 4 cm]F Boulière, M Crepel, P Bigot, et al.
Pageof 38